Corcept Therapeutics: FDA Approval as a Gamechanger - Oncology Breakthrough as a Price Driver

FDA Approval as a Historic Milestone For Corcept Therapeutics (CORT) , late March 2026 marks a pivotal moment in the company's history. With the recent FDA approval of Lifyorli (Relacorilant) in combination with Nab-Paclitaxel for the treatment of platinum-resistant ovarian cancer, the company has achieved a significant strategic breakthrough. From management's perspective, this approval, based on the compelling efficacy data from the pivotal ROSELLA study, represents not only a medical success but also the long-awaited validation of the company’s...